The increasing use of prophylactic mastectomy in the prevention of breast cancer

Current Oncology Reports

Volumn 12, Issue 1, 2010, Pages 16-21

  Tuttle, Todd M ^a   Abbott, Andrea ^a   Arrington, Amanda ^a   Rueth, Natasha ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Prophylactic mastectomy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; GENE MUTATION; HUMAN; MASTECTOMY; PREVALENCE; REVIEW; RISK REDUCTION; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY;

EID: 76749096756     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0070-y     Document Type: Review

References (46)

1. LC Hartmann DJ Schaid JE Woods, et al. 1999 Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer N Engl J Med 340 77 84 10.1056/NEJM199901143400201 1:STN:280:DyaK1M%2FptFSqsw%3D%3D 9887158 (Pubitemid 29054841)
2. TR Rebbeck T Freibel HT Lynch, et al. 2004 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group J Clin Oncol 22 1055 1062 10.1200/JCO.2004.04.188 14981104 (Pubitemid 41095038)
3. L Lostumbo N Carbine J Wallace, et al. 2004 Prophylactic mastectomy for the prevention of breast cancer Cochrane Database Syst Rev 4 CD002748 15495033
4. GF Robbins JW Berg 1964 Bilateral primary breast cancer: a prospective clinicopathological study Cancer 17 1501 1527 10.1002/1097-0142(196412)17: 12<1501::AID-CNCR2820171202>3.0.CO;2-P 1:STN:280:DyaF2M%2FksVSqtA%3D%3D 14239677
5. HH Storm OM Jensen 1986 Risk of contralateral breast cancer in Denmark 1943-80 Br J Cancer 54 483 492 1:STN:280:DyaL2s%2FgtVCntw%3D%3D 3756084
6. P Prior JA Waterhouse 1981 The incidence of bilateral breast cancer: II. A proposed model for the analysis of coincidental tumours Br J Cancer 43 615 622 1:STN:280:DyaL3M3jt1Khug%3D%3D 7248146
7. HO Adami R Bergstrom J Hansen 1985 Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study Cancer 55 643 647 10.1002/1097- 0142(19850201)55:3<643::AID-CNCR2820550328>3.0.CO;2-L 1:STN:280: DyaL2M%2FnsVSmug%3D%3D 3965112 (Pubitemid 15156037)
8. P Vaittinen K Hemminki 2000 Risk factors and age-incidence relationships for contralateral breast cancer Int J Cancer 88 998 1002 10.1002/1097- 0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0 1:STN:280: DC%2BD3M%2FmsFKltQ%3D%3D 11093827
9. EA Peralta JD Ellenhorn LD Wagman, et al. 2000 Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer Am J Surg 180 439 445 10.1016/S0002-9610(00)00505-5 1:STN:280:DC%2BD3M7lvVWqsQ%3D%3D 11182394 (Pubitemid 32166835)
10. SK McDonnell DJ Schaid JL Myers, et al. 2001 Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer J Clin Oncol 19 3938 3943 1:STN:280:DC%2BD3Mrjt1Cgsg%3D%3D 11579114
11. LJ Herrinton WE Barlow O Yu, et al. 2005 Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project J Clin Oncol 23 4275 4286 10.1200/JCO.2005.10.080 15795415 (Pubitemid 46207002)
12. TC van Sprundel MK Schmidt MA Rookus, et al. 2005 Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers Br J Cancer 93 287 292 10.1038/sj.bjc.6602703 16052221 (Pubitemid 43080030)
13. AE Guiliano S Boolbol A Degnim, et al. 2007 Society of Surgical Oncology: position statement on prophylactic mastectomy Ann Surg Oncol 14 2425 2427 10.1245/s10434-007-9447-z (Pubitemid 47389578)
14. McLaughlin CC, Lillquist PP, Edge SB: Surveillance of prophylactic mastectomy. Cancer 2009 Sep 28 (Epub ahead of print).
15. K Goldflam KK Hunt JE Gershenwald, et al. 2004 Contralateral prophylactic mastectomy. Predictors of significant histologic findings Cancer 101 1977 1986 10.1002/cncr.20617 15389473 (Pubitemid 39425372)
16. CD Lehman C Gatsonis CK Kuhl, et al. 2007 MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer N Engl J Med 356 1295 1303 10.1056/NEJMoa065447 1:CAS:528:DC%2BD2sXjsFGht70%3D 17392300 This article discusses how breast MRI detects occult synchronous contralateral breast cancer in about 3% of patients (Pubitemid 46513295)
17. X Gao SG Fisher B Emami 2003 Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study Int J Radiat Oncol Biol Phys 56 1038 1045 10.1016/S0360-3016(03)00203-7 12829139 (Pubitemid 36794035)
18. D Ford DF Easton M Stratton, et al. 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet 62 676 689 10.1086/301749 1:CAS:528:DyaK1MXlvFeh 9497246 (Pubitemid 28164626)
19. K Metcalfe HT Lynch P Ghadirian, et al. 2004 Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers J Clin Oncol 22 2328 2335 10.1200/JCO.2004.04.033 1:CAS:528:DC%2BD2cXpsVWltbs%3D 15197194 (Pubitemid 41115389)
20. TM Tuttle EB Habermann EH Grund, et al. 2007 Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment J Clin Oncol 25 5203 5209 10.1200/JCO.2007.12.3141 17954711 This article discusses how the use of contralateral prophylactic mastectomy increased by 150% in the United States from 1998 to 2003 (Pubitemid 350232251)
21. NB Jones J Wilson L Kotur, et al. 2009 Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution Ann Surg Oncol 16 2691 2696 10.1245/s10434-009-0547-9 19506956
22. ME Sorbero AW Dick E Burke Beckjord, et al. 2009 Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy Ann Surg Oncol 16 1597 1605 10.1245/s10434-009-0362-3 19330381
23. KA Metcalfe J Lubinski P Ghadirian, et al. 2008 Hereditary Breast Cancer Clinical Study Group. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group J Clin Oncol 26 1093 1097 10.1200/JCO.2007.12.6078 18195327 This article states that nearly 50% of patients with unilateral breast cancer and a BRCA mutation undergo contralateral prophylactic mastectomy in the United States
24. WC Black RF Nease Jr AN Tosteson 1995 Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age J Natl Cancer Inst. 87 720 31 10.1093/jnci/87.10.720 1:STN:280:DyaK28%2FgtFehsA%3D%3D 7563149
25. NE Alexander J Ross W Sumner, et al. 1996 The effect of an educational intervention on the perceived risk of breast cancer J Gen Intern Med 11 92 97 10.1007/BF02599584 1:STN:280:DyaK28vivFyltA%3D%3D 8833016
26. A Partridge K Adloff E Blood, et al. 2008 Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study J Natl Cancer Inst 100 243 251 10.1093/jnci/djn010 18270338
27. E Rakovitch E Franssen J Kim, et al. 2003 A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer Breast Cancer Res Treat 77 285 293 10.1023/A: 1021853302033 12602928 (Pubitemid 36197643)
28. D Schrag KM Kuntz JE Garber, et al. 2000 Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations JAMA 283 617 624 10.1001/jama.283.5.617 1:STN:280: DC%2BD3c7islCltQ%3D%3D 10665701
29. LA Woerdeman JJ Hage MJ Smeulders, et al. 2006 Skin-sparing mastectomy and immediate breast reconstruction by use of implants: an assessment of risk factors for complications and cancer control in 120 patients Plast Reconstr Surg 118 321 330 10.1097/01.prs.0000234049.91710.ba 1:CAS:528:DC%2BD2sXlvFymtA%3D%3D 16874196 (Pubitemid 44162033)
30. MH Frost JM Slezak NV Tran, et al. 2005 Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance J Clin Oncol 23 7849 7856 10.1200/JCO.2005.09.233 16204003 (Pubitemid 46657383)
31. LL Montgomery KN Tran MC Heelan, et al. 1999 Issues of regret in women with contralateral prophylactic mastectomies Ann Surg Oncol 6 546 552 10.1007/s10434-999-0542-1 1:STN:280:DyaK1MvitFeltw%3D%3D 10493622 (Pubitemid 29428793)
32. AM Geiger CN West L Nekhlyudov, et al. 2006 Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy J Clin Oncol 24 1350 1356 10.1200/JCO.2005.01.9901 16549829 (Pubitemid 46621997)
33. A Altschuler L Nekhlyudov S Rolnick, et al. 2008 Positive, negative, and disparate women's differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy Breast J 14 25 33 10.1111/j.1524-4741. 2007.00521.x 18186862
34. K Metcalfe MJ Esplen V Goel, et al. 2004 Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy Psychooncology 13 14 25 10.1002/pon.726 14745742 (Pubitemid 38139354)
35. S Ciatto D Ambrogetti R Bonardi, et al. 1990 Prognostic impact of early detection of contralateral primary breast cancer Tumori 76 370 373 1:STN:280:DyaK3cznvVGjtA%3D%3D 2399567
36. WA Mellink R Holland JH Hendriks, et al. 1991 The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer Cancer 67 1844 1848 10.1002/1097-0142(19910401)67:7<1844::AID- CNCR2820670705>3.0.CO;2-W 1:STN:280:DyaK3M7mvVSlsQ%3D%3D 1848469
37. B Fisher C Redmond 1991 New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent J Natl Cancer Inst 83 1278 1280 10.1093/jnci/83.18.1278 1:STN:280:DyaK3MzlvFentg%3D%3D 1832192
38. HJ Stewart 1992 The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group J Natl Cancer Inst Monogr 11 117 120 1320920
39. LE Rutqvist B Cedermark U Glas, et al. 1991 Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy J Natl Cancer Inst 83 1299 1306 10.1093/jnci/83.18.1299 1:STN:280: DyaK3MzlvFemsw%3D%3D 1886157
40. M Baum AU Budzar J Cuzick, et al. 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 10.1016/S0140-6736(02)09088-8 1:CAS:528:DC%2BD38XkslGhsLY%3D 12090977 (Pubitemid 34694019)
41. JW Meakin JL Hayward T Panzarella, et al. 1996 Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast Breast Cancer Res Treat 37 11 19 10.1007/BF01806627 1:CAS:528:DyaK28XhsFSisrc%3D 8750523 (Pubitemid 26028241)
42. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467.
43. TM Tuttle S Jarosek E Habermann, et al. 2009 Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ J Clin Oncol 27 1362 1367 10.1200/JCO.2008.20.1681 19224844
44. ER Fisher J Dignam E Tan-Chiu, et al. 1999 Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma Cancer 86 429 438 10.1002/(SICI)1097-0142(19990801) 86:3<429::AID-CNCR11>3.0.CO;2-Y 1:STN:280:DyaK1Mzlslehsg%3D%3D 10430251 (Pubitemid 29347405)
45. B Fisher J Dignam N Wolmark, et al. 1999 Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1993 2000 10.1016/S0140-6736(99) 05036-9 1:CAS:528:DyaK1MXkt1Cnsrk%3D 10376613 (Pubitemid 29271743)
46. J Houghton WD George J Cuzick, et al. 2003 Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial Lancet 362 95 102 10.1016/S0140-6736(03)13859-7 12867108 (Pubitemid 36831018)